Experts hold out hope for Healthpoint's spray-on cell therapy for venous leg ulcers
This article was originally published in Scrip
Healthpoint Biotherapeutics is to start a US Phase III trial of its novel cell-based treatment for venous leg ulcers HP802-247 later this year, with a similar study due to follow shortly after in the EU, based on highly promising Phase II data just published in The Lancet.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.